Heart failure & cardiomyopathies
Beta-Blockers and Long-Term Mortality in Takotsubo Syndrome: Results of the Multicenter GEIST Registry
Main finding · MortalityResult — go to the resultHazard ratio 0.71 95% CI 0.55–0.90Authors' conclusion
Beta-blocker therapy in patients with TTS is associated with lower follow-up mortality, but not with lower TTS recurrence.
Study context
- Population
- Patients discharged with confirmed Takotsubo syndrome (TTS), GEIST registrymatched: 2 groups of 697
- Participants
- 2,853 patients
- Exposure
- Beta-blockers at discharge vs no beta-blockers
- Beta-blockersn = 2,125
- Outcome
- Long-term mortality
- Follow-up
- Mean 2.6 years
Methodological detailsinternational multicentre registry, propensity-score matched
- International multicentre registry
- Propensity-score matched
Main finding
Mortality
Hazard ratio
0.71
95% CI 0.55–0.90
By group
Beta-blockers
6.0 per 100 patients/year
No beta-blockers
8.1 per 100 patients/year
Beta-blockersvs No beta-blockers
HR 0.71 (95% CI 0.55–0.90)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| TTS recurrence · mean follow-up 2.6 years | 0.74 (0.61–1.89) | |
| 0.512Hazard ratio (log scale) |
- TTS recurrence: Overall: 97 (3.4%) had TTS recurrence
LVEF recovery
- No association between beta-blockers at discharge and LVEF recovery
Original publication
Beta-Blockers and Long-Term Mortality in Takotsubo Syndrome: Results of the Multicenter GEIST Registry. JACC Heart Fail. Published 5 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →